Companies › Beacon Therapeutics
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rAAV2tYF-GRK1-RPGR Adeno-associated virus vector expressing human RPGR gene | RPGR | Phase 2 | X-Linked Retinitis Pigmentosa | Feb 2027 |
| Laruparetigene zovaparvovec (AGTC-501) Adeno-associated virus vector expressing human RPGR gene | RPGR | Phase 2 | X-Linked Retinitis Pigmentosa (XLRP); X-Linked Retinitis Pigmentosa | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03316560 | rAAV2tYF-GRK1-RPGR | Phase 1 | X-Linked Retinitis Pigmentosa | Ophthalmology | Nov 2023 |
| NCT06333249 | rAAV2tYF-GRK1-RPGR | Phase 2 | X-Linked Retinitis Pigmentosa | Ophthalmology | Feb 2027 |
| NCT07174726 | Laruparetigene zovaparvovec (AGTC-501) | Phase 2 | X-Linked Retinitis Pigmentosa (XLRP) | Ophthalmology | Dec 2029 |
| NCT04850118 | Laruparetigene zovaparvovec (AGTC-501) | Phase 2 | X-Linked Retinitis Pigmentosa | Ophthalmology | Oct 2031 |
MeiraGTx Ocular UK jCyte NovaSight Emmecell Price Vision Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.